Qynapse Further Strengthens Its Leadership Team With The Appointment Of Adam Schwarz, Ph.D., As Scientific Director


Posted: October 21, 2021 at 7:00 a.m. MDT|Update: 56 minutes ago

BOSTON, October 21, 2021 / PRNewswire / – Qynapse Inc., a medical technology company that markets an AI-based neuroimaging software platform for central nervous system (CNS) disorders, today announced the appointment of Adam J. Schwarz, Ph.D., as Scientific Director (CSO). In his new role, Dr Schwarz is responsible for designing and developing Qynapse’s scientific research strategies and operations, and for expanding and communicating their product offering and scientific validation to scientific communities and customers. Dr Schwarz brings over 20 years of experience in the global pharmaceutical industry with a focus on translational and clinical imaging, both MRI and PET, in a range of psychiatric and neurological disorders.

Adam J. Schwarz, Ph.D. – Scientific Director Qynapse

Prior to Qynapse, Dr. Schwarz held key scientific leadership roles, leading the Clinical Imaging group at Takeda Pharmaceuticals and holding several positions including Chief Imaging Officer for over a decade at Eli Lilly and Company.

“We are delighted to welcome Adam to our leadership team to lead Qynapse’s research and scientific priorities, in line with our overall mission to continually advance our breakthrough technology for healthcare and clinical trials and to solidify our excellence. scientific, ”said the CEO of Qynapse. , Olivier Courrèges.

“I am extremely excited to help advance and expand Qynapse’s suite of innovative image analysis tools as key enablers for improved healthcare and more efficient clinical trials. , improving personalized medicine approaches through sophisticated patient-level profiling, ”said Adam schwarz.

Adam schwarz holds a B.Sc. with honors in physics and a doctorate. in Electrical and Electronic Engineering, both from the University of Canterbury (New Zealand), followed by a postdoctoral fellowship as an imaging physicist at the Institute of Cancer Research / Royal Marsden Hospital in London, United Kingdom, and early career positions at Marconi Medical Systems in Farnham, UK, and GlaxoSmithKline in Verona, Italy.

Throughout his career, he has developed and maintained strong relationships with academic groups, specialist companies and consortia to advance the science and application of imaging as a tool to better understand disease mechanisms. and improve drug development. Dr Schwarz has an active scientific profile and is the author of over 100 peer-reviewed articles, two books and several guest book chapters.

About Qynapse Inc .:

Qynapse Inc. is a medical technology company that markets a proprietary AI-based neuroimaging software platform that creates the potential for earlier clinical precision on the front lines of CNS disease.

Qynapse’s flagship solution, QyScore®, FDA approved and CE marked, combines MRI scans and artificial intelligence to produce rapid and actionable information on CNS disorders, adding the potential for more precise analysis and objective brain analyzes. Qynapse’s predictive AI technology, QyPredict®, available for research purposes only, has the potential to predict disease trajectory and improve targeted patient selection in clinical trials.

Qynapse is headquartered at France, in United States and in Canada.

Contact:
Ysé Sallé de Chou
[email protected]

Photo – https://mma.prnewswire.com/media/1666906/QYNAPSE_Schwarz.jpg
Logo – https://mma.prnewswire.com/media/1628911/QYNAPSE_Logo.jpg

(PRNewsfoto / QYNAPSE)
(PRNewsfoto / QYNAPSE)

View original content to download multimedia:

SOURCE QYNAPSE

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.


Source link

Previous Theranos blood test demonstration machines hid errors, court said • The Register
Next Can Quantum Computing Reorient Our Supply Chain Problems

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *

MENU

Back